» Articles » PMID: 1978026

Clearance of Rh D-positive Red Cells with Monoclonal Anti-D

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1990 Nov 10
PMID 1978026
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Two human monoclonal antibodies, one IgG3 and one IgG1, with anti-Rh D specificity, were tested for their ability to clear red cells. Samples of red cells from 12 D-positive subjects were sensitised in vitro with various amounts of antibody, the number of antibody molecules bound to the cells was estimated, and the cells were reinjected into the donor's circulation. Both antibodies mediated clearance but substantially fewer IgG3 than IgG1 antibody molecules were required to produce a given rate of clearance. The IgG3 antibody was slightly more effective than polyclonal anti-D, as judged by comparison with previously published results. Since there is believed to be an association between the rate of red cell clearance by anti-D and the ability of the antibody to suppress D immunisation, the IgG3 monoclonal antibody may prove suitable for the immunoprophylaxis of Rh D haemolytic disease.

Citing Articles

Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy.

Kumpel B, Saldova R, Koeleman C, Abrahams J, Ederveen A, Armour K Sci Rep. 2020; 10(1):1464.

PMID: 32001734 PMC: 6992666. DOI: 10.1038/s41598-019-57393-9.


Clearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines.

Armour K, Smith C, Ip N, Ellison C, Kirton C, Wilkes A PLoS One. 2014; 9(10):e109463.

PMID: 25302805 PMC: 4193810. DOI: 10.1371/journal.pone.0109463.


The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation.

Liumbruno G, DAlessandro A, Rea F, Piccinini V, Catalano L, Calizzani G Blood Transfus. 2010; 8(1):8-16.

PMID: 20104273 PMC: 2809506. DOI: 10.2450/2009.0108-09.


Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.

Kumpel B Clin Exp Immunol. 2008; 154(1):1-5.

PMID: 18727626 PMC: 2561090. DOI: 10.1111/j.1365-2249.2008.03735.x.


The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodies.

Chapman G, Ballinger J, Norton M, Parry-Jones D, Beharry N, Cousins C Clin Exp Immunol. 2007; 150(1):30-41.

PMID: 17680827 PMC: 2219283. DOI: 10.1111/j.1365-2249.2007.03458.x.